Differentiation between recurrent brain tumour and post-radiation necrosis the value of 201t1 spet versus l8f-fdg pet using a dual-headed coincidence camera – a pilot study

Nuclear Medicine Communications

Volumn 20, Issue 5, 1999, Pages 411-418

  Stokkel, M ^a   Stevens, H ^a   Taphoorn, M ^a   Van Rijk, P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THALLIUM 201;

ADULT; ARTICLE; BRAIN CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSITRON EMISSION TOMOGRAPHY; RADIATION NECROSIS; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MALE; MIDDLE AGED; NECROSIS; OLIGODENDROGLIOMA; PILOT PROJECTS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY; RECURRENCE; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032989863     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199905000-00003     Document Type: Article

References (38)

1. Janus TJ, Kyritsis AP, Forman AD, Levin VA. Biology and treatment of gliomas. Ann Oncol 1992; 3: 423-433.
2. Burger PC. Malignant astrocytic neoplasms: Classification, pathologic anatomy and response to treatment. Sem Oncol 1986; 13: 16-26.
3. Cairncross JG, Pexman JHW, Rathbone MP. Post-surgical contrast enhancement mimicking residual brain tumor. Can J Neurol Sci 1985; 12: 75.
4. Cairncross JG, Pexman JHW, Rathbone MP, DelMaestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 1985; 17: 570-572.
5. Jeffries BF, Kishoe PRS, Singh KS et al. Contrast enhancement in the postoperative brain. Radiology 1981; 149: 409-413.
6. Graeb DA, Steinbok P, Robertson WD. Transient early computed tomographic changes mimicking tumor progression after brain tumour irradiation. Radiology 1982; 144: 813-817.
7. Kline JL, Noto RB, Glantz MJ. Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy. Am J Neuroradiol 1996; 17: 1681-1686.
8. Lorberboym M, Baram J, Feibel M, Hercbergs A, Lieber-man L. A prospective evaluation of thallium-201 single photon emission computerized tomography for brain tumor burden, Int J Radiat Oncol Biol Phys 1995; 32: 249-254.
9. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL. Thallium-201 brain tumour imaging: A comparative study with a pathologic correlation. J Nucl Med 1987; 28: 47-52.
10. Glantz MJ, Hoffman JM, Coleman RE et al. Identification of early recurrence of primary central nervous system tumors by (18F) fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347-355.
11. Di Chiro G, Oldfield E, Wright DC et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumours: PET and neuropathological studies. AJR 1988; 150: 189-197.
12. Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma: A predictor of prognosis. Cancer 1988; 62: 1074-1078.
13. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral glioma using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991; 10: 85-91.
14. Brisma T, Collins VP, Kesselberg M. Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells. Brain Res 1989; 500: 30-36.
15. Sehweil AM, McKillop JH, Milroy R, Wilson R, Abdel-Dayem HM, Omar YT. Mechanism of Tl-201 in tumours. Eur J Nucl Med 1989; 15: 376-379.
16. Kim KT, Black KL, Marciano D et al. Thallium-201 SPECT imaging of brain tumors: Methods and results. J Nucl Med 1990; 31: 965-969.
17. Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989; 71: 342-346.
18. Ueda T, Kaji Y, Wakisaka S et al. Time sequential single photon emission computed tomography studies in brain tumour using thallium-201. Eur J Nucl Med 1993; 20: 138-145.
19. Dierckx RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP. Sensitivity and specificity of thallium-201 singlephoton emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 1994; 21: 621-633.
20. Moustafa HM, Omar WM, Ezzat I, Ziada GA, El-Ghonimy EG. Tl-201 single photon emission tomography in the evaluation of residual and recurrent astrocytoma. Nucl Med Commun 1993; 15: 140-143.
21. Schwartz RB, Carvalho PA, LA EA, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma: Differentiation by using dual-isotope SPECT with Tl-201 and Tc-99m HMPAO. Am J Neuroradiol 1992; 12: 1187-1192.
22. Carvalho PA, Schwartz RB, LA EA et al. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m-HMPAO single-photon emission computerized tomography. J Neurosurg 1992; 77: 565-570.
23. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial bra-chytherapy. J Neurosurg 1988; 69: 830-838.
24. Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by F18-FDG and Rb-82 positron emission tomography. J Comput Assist Tomogr 1987; 11: 563-570.
25. Hoh CK, Khanna S, Harris GC et al. Evaluation of brain tumor recurrence with Tl-201 SPECT studies: Correlation with FDG PET and histological results. J Nucl Med 1992; 33: 867.
26. Kahn D, Follet KA, Bushnell DL et al. Diagnosis of recurrent brain tumour: Value of Tl-201 SPECT vs F-18-fluoro-deoxyglucose PET. Am J Radiol 1994; 163: 1459-1465.
27. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995; 36: 159-164.
28. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of F-18 fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33: 540-548.
29. Tyler JL, Diksic M, Villemure J-G et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987; 28: 1123-1133.
30. Delbeke D, Meyerowitz C, Lapidus R et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in differentiation of low-grade from high-grade brain tumours with PET. Radiology 1995; 195: 47-52.
31. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991; 32: 616-622.
32. Di Chiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360-371.
33. Saha GB, MacIntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. Sem Nucl Med 1994; 4: 324-349.
34. Ishizu K, Nishizawa S, Yonekura Y et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994; 35: 1104-1109.
35. Ishizu K, Sadato N, Yonekura Y et al. Enhanced detection of brain tumours by [F18]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 1994; 18: 12-15.
36. Weber W, Bartenstein P, Gross MW et al. Fluorine-18 FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997; 38: 802-808.
37. Woesler B, Kuwert T, Morgenroth C et al. Non-invasive grading of primary brain tumors: Results of a comparative study between SPET with I123-a-methyl tyrosine and PET with F18-deoxyglucose. Eur J Nucl Med 1997; 24: 428-434.
38. Biersack HJ, Coenen HH, Stocklin G et al. Imaging of brain tumors with L-3-[I123]iodo-a-methyl tyrosine and SPECT. J Nucl Med 1989; 30: 110-112.